Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
Kumquat Biosciences Inc.
Dana-Farber Cancer Institute
Stanford University
M.D. Anderson Cancer Center
Institute of Hematology & Blood Diseases Hospital, China
Hoffmann-La Roche
Novartis
OHSU Knight Cancer Institute
Barbara Ann Karmanos Cancer Institute
St. Jude Children's Research Hospital
Jonsson Comprehensive Cancer Center
OHSU Knight Cancer Institute
Bristol-Myers Squibb
Barbara Ann Karmanos Cancer Institute
Northwestern University
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Emory University
University of Utah
University of Massachusetts, Worcester
Bristol-Myers Squibb
University of Pittsburgh
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Jonsson Comprehensive Cancer Center
City of Hope Medical Center
Bristol-Myers Squibb
Bristol-Myers Squibb